"As new variants of SARS-CoV-2 continue to emerge, it is important to assess the cross-neutralizing capabilities of antibodies naturally elicited during wild type SARS-CoV-2 infection. In the present study, we evaluate the activity of nine anti-SARS-CoV-2 monoclonal antibodies (mAbs), previously isolated from convalescent donors infected with the Wuhan-Hu-1 strain, against the SARS-CoV-2 variants of concern (VOC) Alpha, Beta, Gamma, Delta and Omicron...
Discussion: ... To summarize, our study provides functional and atomic-level structural data on the interactions between naturally elicited antibodies and SARS-CoV-2 variants. Both TAU-2303 and TAU-2212 are potently neutralizing but arise through different B cell developmental programs. Neutralization by TAU-2212 is successful for most of the mutations with the exception of E484K. We therefore conclude that combining mAbs that can bind E484K, such as TAU-1109, −2303 or −2310 with TAU-2212 may be useful for broad spectrum anti-viral neutralization."
Copyright © 2022, The Author(s)
This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.